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What is already known about this topic? 
• Rosacea is a chronic facial inflammatory dermatosis 
• The diagnosis and classification of rosacea have evolved from a subtype to a phenotype 
approach 
• Effective and safe interventions include brimonidine in temporarily reducing persistent 
erythema; laser and light based therapies for mainly telangiectasia; topical azelaic acid, 
metronidazole and ivermectin, along with oral doxycycline and isotretinoin for 
papules/pustules; and topical ciclosporin ophthalmic emulsion for ocular rosacea 
 
What does this study add? 
• Phenotype-based approach with GRADE certainty of evidence assessments 
• Topical oxymetazoline reduces temporarily persistent erythema  (moderate certainty 
evidence) 
• There is moderate certainty of evidence that topical minocycline is effective in treating 
papules/pustules, and oral minocycline is as effective as doxycycline 40 mg 
• Low dose isotretinoin 0.25 mg/kg greatly reduces papules/pustules compared to placebo 
(high certainty evidence) 
• Omega-3 fatty acids improve symptoms of dry eyes and tear gland function (moderate 







Rosacea is a common chronic facial dermatosis. Classification of rosacea has evolved from subtyping 
to phenotyping. 
Objectives 
Updating our systematic review on interventions for rosacea.  
Methods 
We searched: CENTRAL in The Cochrane Library, MEDLINE, EMBASE, LILACS, Science Citation Index, 
and ongoing trials registers (March 2018) for randomised controlled trials. Study selection, data 
extraction, risk of bias assessment and analyses were carried out independently by two authors. 
GRADE was used to assess certainty of evidence. 
Results 
We included 152 studies (46 were new), comprising 20,944 participants. Topical interventions 
included: brimonidine, oxymetazoline, metronidazole, azelaic acid, ivermectin and other topical 
treatments. Systemic interventions included: oral antibiotics, combinations with topical treatments 
or other systemic treatments. Several studies evaluated laser or light-based treatment. 
We present the most current evidence for rosacea management based on a phenotype-led 
approach.  
Conclusions 
For reducing temporarily persistent erythema: there was high certainty evidence for topical 
brimonidine and moderate certainty for topical oxymetazoline; for erythema and mainly 
telangiectasia: low to moderate certainty evidence for laser and intense pulsed light therapy. 
For reducing papules/pustules: there was high certainty evidence for topical azelaic acid and topical 
ivermectin; moderate to high certainty evidence for doxycycline and isotretinoin; moderate certainty 
evidence for topical metronidazole, and topical minocycline and oral minocycline being equally 
effective as doxycycline 40 mg. There was low certainty evidence for tetracycline and low dose 
minocycline. 
For ocular rosacea, there was moderate certainty evidence that oral omega-3 fatty acids were 





Rosacea is a chronic inflammatory dermatosis affecting the cheeks, nose, eyes, chin and forehead. It 
is characterised by recurrent episodes of flushing or transient erythema, persistent erythema, 
papules, pustules, and telangiectasia.1-4 In 2002, the National Rosacea Society Expert Committee 
(NRSEC) of the United States proposed standardised criteria for diagnosis and classification of 
rosacea.5 They posited that any one of the following primary features in a centrofacial distribution 
sufficed for diagnosis: flushing, non-transient erythema, papules/pustules or telangiectasia. 
Secondary features included burning/stinging, erythematous plaques, dry appearance, oedema, 
peripheral location, phymatous changes and ocular manifestations. Furthermore, they grouped 
some of these features into four subtypes and one variant: erythematotelangiectatic, 
papulopustular, phymatous, ocular and granulomatous rosacea (the variant).5 
However, shortcomings in these diagnostic criteria and subtyping have become apparent.6  This 
includes the lack of specificity of some primary features (flushing, papules/pustules, telangiectasia), 
the exclusion of phyma as a primary feature, and the conflation of multiple features into subtypes.6 
For example, the erythematotelangiectatic subtype comprises flushing and persistent central facial 
erythema with, or without telangiectasia while the papulopustular subtype comprises persistent 
central facial erythema with transient, central facial papules and/or pustules. Thus, both have 
persistent central facial erythema as a common feature. This has led to confusion in epidemiological 
research whereby some studies consider them as separate categories while others aggregate all with 
central facial erythema as erythematotelangiectatic, a subgroup of which is papulopustular. 
Furthermore, it does not account for patients presenting with a solitary diagnostic criterion and 
absence of the others defining a specific subtype. For example, how would one classify a patient 
with persistent central facial erythema alone but without flushing and telangiectasia? In addition, 
severity determination of subtypes is complicated by the presence of multiple features each of 
which may vary in individual severity and responsivity to intervention. However, these individual 
features were not previously typically evaluated separately. Furthermore, in clinical practice, 
subtyping may inadequately capture the signs and symptoms of individual patients as some features 
can extend across subtypes. 
Consequently, revised diagnostic criteria have been proposed and recommendations made to 
abandon the subtyping approach. Both an international Rosacea Consensus panel and updated 
NRSEC guidance have recommended harmonized diagnostic criteria and a phenotype-led 
approach.6,7  The following features represent independent diagnostic criteria of rosacea: fixed 
centrofacial erythema that may periodically intensify, or phymatous changes. In their absence, 
diagnosis can also be established by two or more major features: papules/pustules, flushing, 
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telangiectasia, ocular manifestations (lid margin telangiectasia, interpalpebral conjunctival injection, 
spade shaped infiltrates in the cornea, scleritis and sclerokeratitis).7 While secondary features may 
occur - burning or stinging, oedema, dry appearance – these are not generally considered diagnostic, 
either alone or in combination. This redirection in diagnosis and elimination of subtypes should 
provide greater accuracy in diagnosis, establish clearly defined targets for research, facilitate 
development of severity measures and improve patient-centred care.7 
Management strategies for people with rosacea should include phenotype-based treatments, in 
accordance with current classification of rosacea (instead of the previous subtype-classification).7,8 
As rosacea can have an adverse impact on quality of life, these strategies should also be directed 
towards achieving improvements in general well-being by targeting those aspects most bothersome 
to the patient.1,8,9 
The objectives of this systematic review were to examine the different management options and to 
determine the most effective strategies in the treatment of rosacea. Furthermore, this review more 
closely aligns evidence-based treatment options with the new phenotype approach. 
As the Cochrane Skin Group recently decided to facilitate the regular update of only a few systematic 
reviews, this update of the Cochrane review is published in the British Journal of Dermatology. The 
content of the full updated review is provided in Supplementary file 1.  
 
MATERIAL AND METHODS 
This updated systematic review conforms to the PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) statement10 and followed a prespecified protocol.11  
Inclusion criteria 
Randomised controlled trials (RCTs) examining all types of interventions in people with rosacea. 
Outcome measures 
Our primary outcomes were: quality of life, participant-assessed rosacea severity and proportion of 
participants reporting an adverse event. Secondary outcome measures were physician-assessed 
rosacea severity, assessment of erythema and telangiectasia, lesion counts, time to improvement 
and duration of remission. 
Search strategies 
We searched several databases to 6 March 2018: CENTRAL in The Cochrane Library, MEDLINE, 
EMBASE, LILACS, and Science Citation Index, for the search strategies see Supplementary file 1. 
Furthermore, E.J.v.Z. and M.v.d.L searched trials registers on 13 March 2018 with the terms 'rosacea' 
and 'rhinophyma': metaRegister of Controlled Trials (www.controlled-trials.com), U.S. National 
Institutes of Health Ongoing Trials Register (www.clinicaltrials.gov), Australian and New Zealand 
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Clinical Trials Registry (www.anzctr.org.au), World Health Organization International Clinical Trials 
Registry platform (www.who.int/trialsearch), the Ongoing Skin Trials Register 
(www.nottingham.ac.uk/ongoingskintrials). Two authors (E.J.v.Z., Z.F.) examined the bibliographies 
of included and excluded studies for further potentially eligible studies. We did not apply language 
restrictions and several articles were translated. Two authors independently assessed the titles and 
abstracts from the searches (E.J.v.Z., Z.F.). The same two authors independently assessed the 
obtained full-text papers of all potentially eligible included studies. Disagreements were resolved 
through discussion.   
Data extraction and risk of bias assessment 
Study details and outcome data were collected independently by two authors (E.J.v.Z. and Z.F.) using 
a piloted data extraction form. Disagreements on data entry were resolved through discussion. The 
following details were extracted: design, year of publication, setting, country of origin, number, 
gender and age of participants, ocular involvement, drop-outs and losses to follow-up, intervention, 
outcomes, baseline data, funding and conflict of interest. Two authors (E.J.v.Z., Z.F.) independently 
assessed risk of bias using the Cochrane Collaboration's domain-based assessment tool.12 
Statistical analysis 
We calculated risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous 
outcomes and their associated 95% confidence interval. When RRs were statistically significant, we 
calculated number needed to treat for one additional beneficial outcome (NNTB) or number needed 
to treat for one additional harmful outcome (NNTH). In the absence of substantial heterogeneity (I2 
statistic < 60%), data reported for our outcomes were pooled using a random effects model, and 
summarised with the I2 statistic. All analyses were undertaken using RevMan 5.3 (The Nordic 
Cochrane Centre, Copenhagen, Denmark). 
Certainty of evidence 
We applied GRADE to assess the certainty of evidence for the prespecified outcomes of the main 
comparisons using GRADEproGDT (http://gradepro.org) to generate Summary of Findings Tables 
(see Supplementary file 1 for details on Methods, Results and 25 Summary of Findings Tables).13 See 
Table 1 for GRADE Working Group grades of evidence. 
RESULTS 
Search results 
The updated searches identified an additional 219 citations. Trial register searching revealed 38 
ongoing studies, totalling 257 references. Fourteen duplicates, and 160 references were excluded 
after examination of titles and abstracts. The remaining 83 studies were assessed for eligibility and 
only 46 were included.14-57 See Figure 1.  
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Description of the studies 
One hundred fifty-two studies were included (eight references report on two studies),14-158 
comprising 20,944 participants (mean age 48.6 years). More women (12,575) than men (5313) were 
included; in 3056 the gender was unreported. Study sample sizes varied from 6 to 1299 participants, 
but most were between 30 and 100. The trials were grouped into 12 categories of interventions: 
topical brimonidine; topical oxymetazoline; topical metronidazole; topical azelaic acid; topical 
ivermectin; topical metronidazole, azelaic acid and/or other topical treatments in different 
treatment arms; oral antibiotics; oral antibiotics combined with topical treatments; oral antibiotics 
compared with topical treatments; other systemic treatments; laser and light-based therapies; and 
other treatments or combined treatments. 
Full details of all included and excluded studies (starting from the original 2004 review) are in 
Supplementary file 1, sections Characteristics of included studies and Characteristics of excluded 
studies. 
Risk of bias in included studies 
Only 16/152 studies were at low risk of bias28,33,51,87,93,135,138-140,147,150,155, 52 were assessed as high risk 
of bias and the remaining 84 studies as at unclear risk of bias. See Figure 2. 
Evidence based treatments 
Of the 152 studies, 34 provided no usable or retrievable data that could contribute to the results 
(see Table 6 in Supplementary file 1).46-79 Important reasons were that none of our outcomes were 
addressed, no separate data for rosacea, or limited data reported in conference abstracts. The 
remaining 118 studies covered 93 comparisons. 
We have summarized pivotal study results in a phenotype-led approach to provide guidance for 
clinical decision making as well as guideline development. Details and results on all 152 studies are 
reported in Supplementary file 1. 
Treatment of transient erythema and flushing 
No RCTs were available. 
Treatment of persistent erythema 
Brimonidine and oxymetazoline are topical α-adrenergic agonists which induce transient 
vasoconstriction of cutaneous superficial blood vessels resulting in reduction of facial erythema after 
application.15,30,138,139  Both reduce erythema within 30 minutes, reaching a peak between three to six 




Two studies (low risk of bias) showed, after three hours, a 2 grade improvement in Patient’s Self 
Assessment of erythema (PSA, 0 to 4, clear to severe) in 114/277 using topical brimonidine 3 mg/g 
gel versus 54/276 using vehicle (RR 2.11, 95% CI 1.60 to 2.78; P < 0.001; I² = 0%; NNTB 5, 95% CI 3 to 
7; high certainty evidence).139 In the brimonidine group adverse events were reported in 88/277 
participants compared to 68/276 in the vehicle group (RR 1.29, 95% CI 0.98 to 1.69; I² = 0%; 
moderate certainty evidence). In both studies, adverse events were mild and transient. Most 
frequently reported were worsening of erythema, flushing, pruritus and skin irritation. During the 
four week follow-up, no rebound erythema was observed. Physicians’ assessments were in accord 
with patients’ assessments (high certainty evidence). 
Oxymetazoline 
In two studies (unclear risk of bias) participants’ assessments using the Subjective Self-Assessment 
(SSA, 0=no signs of unwanted redness, 4=severe redness) showed 2 grade improvement after three 
hours in 99/446 treated with oxymetazoline 1% cream and in 59/439 treated with vehicle (RR 1.65, 
95% CI 1.23 to 2.21; P < 0.001; I² = 0%; NNTB = 11, 95% CI 7 to 27; moderate certainty evidence).15,30 
In the oxymetazoline group 94 adverse events were reported in 446 participants versus 70 in 439 
participants in the vehicle group (RR 1.32, 95% CI 0.97 to 1.78; I² = 13%; moderate certainty 
evidence). Application site dermatitis, pruritus, and erythema, worsening of inflammatory lesions 
and headache were the most reported adverse events and were considered mild or moderate in 
severity. During the 29 days follow-up period six patients in the oxymetazoline group experienced 
rebound erythema versus two in the vehicle group. Physicians’ assessments were in accord with 
patients’ assessments (moderate certainty evidence).  
Treatment of telangiectasia 
Laser and other light-based therapies 
Although widely used for reducing erythema and telangiectasia, only a few small sample size RCTs 
(16 to 49 patients) provided data on laser and light-based therapies (predominantly low certainty 
evidence for various outcomes). There was low to moderate certainty evidence that (long) PDL, 
Nd:YAG laser and intense pulsed light therapy reduce erythema and especially telangiectasia.131,151 
This was supported by several other studies.40,100,110,144 
  
Treatment of papules/pustules 
Topical azelaic acid  
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Azelaic acid is available as 15% gel, 20% cream and 15% foam. Seven studies at unclear risk of bias 
evaluated azelaic acid twice daily versus vehicle.20,35,86,90,123,137 Quality of life was addressed in 
two19,136, but with no to little differences between groups at the end of the study (high certainty 
evidence). In six studies, participants-assessed improvement (marked or excellent) was reached in 
648/1132 with azelaic acid versus 439/1091 with vehicle (RR 1.40, 95% CI 1.28 to 1.53; P < 0.001; I² = 
0%; NNTB = 6, 95% CI 5 to 8).20,35,86,123,137 These results were comparable with physicians’ 
assessments, both high certainty evidence. There was little to no difference in number of 
participants experiencing an adverse event: 200/799 on azelaic acid versus 143/760 with vehicle 
(four studies, RR 1.29, 95% CI 0.92 to 1.81; I2 = 46%; moderate certainty evidence).20,35,86,137 Adverse 
events were transient, mild to moderate intensity, with burning, stinging or irritation most 
commonly reported.  In three studies the lesion count reduction was 10-11 lesions with vehicle 
indicating a treatment effect, but the mean difference (MD) favoured azelaic acid (-3.00 lesions, 95% 
CI -4.13 to -1.86; P < 0.001; I² = 9%; high certainty evidence).20,35,137 Azelaic acid reduced erythema 
slightly (physician-assessed, high certainty evidence).35,86,90,123,137 
Topical ivermectin  
Two studies at low risk of bias compared topical ivermectin 1% cream once daily with vehicle.155 
More participants in the ivermectin group (467/910) experienced improvements in quality of life 
than in the vehicle groups (153/461), and at end of the study patients considered rosacea had "no 
[negative] effect on their overall quality of life" (RR 1.55, 95% CI 1.34 to 1.79; P < 0.001; I² = 0%; 
NNTB = 6, 95% CI 4 to 8; high certainty evidence). Good to excellent improvement was reported by 
615/910 participants with ivermectin compared to 169/461 with vehicle (RR 1.84, 95% CI 1.62 to 
2.09; P < 0.001; I² = 0%; NNTB = 3, 95% CI 3 to 4; high certainty evidence) and physicians’ 
assessments were in concordance (moderate certainty evidence). There was no difference in the 
number of participants experiencing an adverse event (62/1050 with ivermectin versus 45/567 with 
vehicle, RR 0.83, 95% CI 0.54 to 1.28; I² = 26%; moderate certainty evidence).24,155 With ivermectin 
skin burning, pruritus and dry skin were more frequently reported. Reductions in lesion counts 
(three studies) were between 20 and 27 with ivermectin and 12 to 23 with vehicle, with a MD 
between groups of -8.09 lesions (95% CI -9.82 to -6.35; P < 0.001; I² = 52%; high certainty evidence), 
again showing treatment effect of the vehicle.24,155 
Topical metronidazole 
Topical metronidazole is available as 0.75% gel and 1% cream. Nine trials at low to high risk of bias 
compared metronidazole versus placebo.82-85,87,88,91,103,111  Data from three studies could not be 
pooled for participants’ assessments due to substantial heterogeneity (65%) but indicated 
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metronidazole was more effective than placebo (low certainty evidence), which was in line with 
physicians’ assessments of 94/195 improving with metronidazole and 40/139 with placebo (RR 1.98, 
95% CI 1.29 to 3.02; P = 0.002; I² = 44%; moderate certainty evidence).85,88,111 Data from six studies 
showed that 379/1375 participants reported an adverse event with metronidazole compared to 
64/398 with placebo (RR 1.19, 95% CI 0.94 to 1.51; I² = 0%; moderate certainty evidence).83-85,88,103,111 
Adverse events were mild, consisted of pruritus, skin irritation, and dry skin. No SDs were provided 
for lesion counts and erythema, data were skewed but appeared to support those reported as 
physician-assessed improvement (both moderate certainty evidence). 
Topical azelaic acid versus topical metronidazole 
Three studies at unclear risk of bias (total 451 participants) reported contradictory data for this 
comparison (moderate certainty evidence).97,105,130 Azelaic acid might be slightly more beneficial 
when compared to metronidazole (according to participants and physicians) but the difference may 
not be important. Azelaic acid likely results in a small and possibly unimportant increase in adverse 
events when compared with topical metronidazole. Reductions in lesion counts were comparable in 
both groups. 
Topical ivermectin versus topical metronidazole 
Topical ivermectin 1% cream once daily likely improved quality of life slightly more than topical 
metronidazole 0.75% twice daily, based on one study in 962 patients at low risk of bias (RR 1.11, 95% 
CI 1.01 to 1.21; P = 0.02; NNTB = 15, 95% CI 8 to 100; moderate certainty evidence).156 Reduction in 
DLQI was 5.18 in the topical ivermectin group and 3.92 in the topical metronidazole group (both 
meeting minimal important difference (MID)).159,160 Good to excellent improvement based on 
participant’s assessments was reported by 409/478 with ivermectin versus 362/484 with 
metronidazole (RR 1.14, 95% CI 1.07 to 1.22; P < 0.001; NNTB = 10, 95% CI 7 to 17; moderate 
certainty evidence).156 There was no difference in number of participants reporting an adverse 
event. Physicians’ assessments in two studies were in concordance with participants’ 
assessments.20,155 Reduction in lesion counts was 27.70 (SD 8.85) with ivermectin compared to 23.60 
(SD 8.23) with metronidazole (MD -4.10, 95% CI -5.18 to -3.02; P < 0.001; high certainty evidence).156  
Minocycline foam 
Minocycline foam (1.5%, 3% versus vehicle) was evaluated in a 12 week study including 232 
participants at low risk of bias.33 Reductions in overall RosaQoL score was 0.4 with minocycline 
versus 0.2 with vehicle. The investigators report “P = 0.003”, but as RosaQoL MID has not been 
established, data are difficult to interpret.  Mean lesion count reduction was 21.1 (SD 8.1) with 
minocycline versus 7.8 (SD 8.0) with vehicle (MD -13.30, 95% CI -15.82 to -10.78). Investigator’s 
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Global Assessment supported these results. In the minocycline foam group 46/79 reported an 
adverse event versus 31/78 with vehicle (RR 1.47, 95% CI 1.05 to 2.04; P = 0.02; NNTH = 5, 95% CI 3 
to 32). Minocycline related adverse events were eczema, burning sensation or worsening rosacea. 
There was moderate certainty evidence for all outcomes. 
Clindamycin cream or gel 
Two studies at unclear risk of bias (629 participants) indicated clindamycin 1% cream or gel twice 
daily was not more effective than vehicle for any of the outcomes (low to moderate certainty 
evidence).32 
Clindamycin combined with tretinoin gel 
One study at low risk of bias with 87 participants evaluated the combination of clindamycin 
phosphate 1.2% with tretinoin 0.025% in a gel versus placebo.135 No differences between groups 
were seen for quality of life, physician assessments, erythema, and lesion counts, but there were 
more adverse events in the active treatment group such as dry skin, scaling and worsening of 
rosacea. Moderate certainty evidence for all outcomes. 
Remaining topical treatments 
Studies evaluating permethrin, dapsone, sodium sulphacetamide with sulphur, pimecrolimus and 
some more unusual treatments (e.g. tranexamic acid, P-3075 cream, SEI003 cream, praziquantel 
ointment, diclofenac sodium gel, incobotulinumtoxinA injections, kanuka honey) were at unclear to 
high risk of bias, inadequately reported or provided very limited data, but are addressed in 
Supplementary file 1.  
Oral tetracyclines 
Two short studies (four and six weeks) including a total of 151 participants, at unclear risk of bias, 
compared oral tetracycline 250 mg twice daily with placebo.106,121 The certainty of evidence was low 
for all outcomes. Tetracycline may result in a large reduction in lesion count, which is supported by 
physician-assessed improvement in rosacea severity. However, patients considered there was no 
difference in effectiveness between tetracycline and placebo.106 
Two studies at low risk of bias93 and two studies at unclear risk of bias19,34 assessed doxycycline 40 
mg versus placebo. None assessed participant-assessed rosacea severity. There was high certainty 
evidence that more participants with doxycycline 40 mg reached  IGA clear or almost clear (91/353) 
than with placebo (53/354)(RR 1.69, 95% CI 1.26 to 2.28; P < 0.001; I² = 0%; NNTB = 9, 95% CI 6 to 
20).19,93 One study was excluded from pooling (I² = 70%) due to lower number of lesions at 
baseline.19 The MD of pooled data was -5.51 lesions (95% CI -7.81 to -3.21; P < 0.001; I² = 0%; 
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moderate certainty evidence).93 Doxycycline 40 mg probably reduced erythema slightly based on 
three studies and assessed with CEA (MD -0.48 (95% CI -0.97 to 0.00; P = 0.05; I² = 28%; moderate 
certainty evidence).19,93 Slightly more adverse events occurred with doxycycline 40 mg (RR 1.27, 95% 
CI 1.08 to 1.49; moderate certainty evidence) but the majority was considered mild or moderate in 
both groups.19,34,93 
Low certainty evidence from one study (91 participants) at unclear risk of bias showed that 40 mg 
doxycycline is at least as effective as 100 mg, with fewer side effects.94 
A non-inferiority study of minocycline 100 mg with doxycycline 40 mg was assessed as at unclear risk 
of bias.43 Patients’ assessments showed that 22/40 participants with minocycline achieved excellent 
or good improvement compared with 20/40 in the doxycycline 40 mg group (RR 1.10, 95% CI 0.72 to 
1.67; low certainty evidence). These findings were in accordance with lesion count reductions. 
Quality of life was assessed using RosaQol and the MD was -0.24 (95% CI -0.30 to -0.18; P < 0.001; 
low certainty evidence), a small and possibly unimportant difference favouring minocycline.  
Physicians’ assessments based on IGA (clear or near clear) favoured minocycline (RR 3.43, 95% CI 
1.67 to 7.04; P < 0.001; NNTB = 2, 95% CI 2 to 4; high certainty evidence). There was no difference in 
number of patients experiencing an adverse event (RR 1.17, 95% CI 0.83 to 1.65; low certainty 
evidence) with the adverse events being similar (e.g. gastro-intestinal side effects and headache).  
In one study (unclear risk of bias) with 60 participants, minocycline 45 mg with or without topical 
azelaic acid demonstrated similar effectiveness in reducing inflammatory lesions 2013)(low certainty 
of the evidence).142 There was a reduction of 11 to 12 lesions in both treatment arms. 
Azithromycin versus doxycycline 
Azithromycin 500 mg three times a week (and then tapered) versus doxycycline 100 mg daily was 
evaluated in one study at high risk of bias (67 participants).80 There were no differences in 
effectiveness and safety for any of the outcomes (very low certainty evidence). Both treatments 
reduced inflammatory lesions by 16 to 18 lesions within three months. 
Isotretinoin versus placebo 
Low dose isotretinoin 0.25 mg/kg was compared to placebo over four months in difficult to treat 
‘papulopustular’ rosacea (cycline-refractory or frequently relapsing) in a study at unclear risk of 
bias.39 After four months, participants assessed satisfaction on a VAS rated from 0 to 100 (higher 
being better) showed median values of 80 in the isotretinoin group versus 9 in the placebo group 
(low certainty evidence). Isotretinoin likely improves quality of life as measured with the Skindex 
(moderate certainty evidence) with scores showing median relative variations of -49.4% in the 
isotretinoin-treated group (108 participants) compared with -18.0% in the placebo group (48 
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participants)(investigators reported "P = 0.002"). Sixty-two of 108 (57.4%) treated with isotretinoin 
reached 90% reduction in inflammatory lesion count versus 5/48 (10.4%) in the placebo group RR 
5.51 (95% CI 2.37 to 12.83; P < 0.001; NNTB = 2, 95% CI 2 to 3; high certainty evidence). The median 
reduction in lesion count was 13 lesions (92% reduction) in the isotretinoin-treated group and 6 
lesions in the placebo group (36%). This was supported by the physicians’ assessments. Treatment 
related adverse events were more frequently reported in the group treated with isotretinoin 
(75/108 (69.4%)) than with placebo (21/48 (43.4%))(RR 1.59, 95% CI 1.12 to 2.24; P = 0.009; NNTH = 
4, 95% CI 2 to 11; moderate certainty evidence). Eczema, cheilitis, dry skin, abdominal pain, 
myalgias/arthralgias and dry eyes, which are well known side effects of isotretinoin, were reported 
in the active treatment group. 
Isotretinoin versus doxycycline 
One study at low risk of bias examined low dose isotretinoin 0.3 mg/kg versus doxycycline 100 mg 
for 14 days and then tapered to 50 mg.140 A small difference in favour of isotretinoin was observed in 
participants’ assessments (total of 261 participants) of good to excellent improvements (RR 1.23, 
95% CI 1.05 to 1.43; P = 0.009; NNTB 7, 95% CI 4 to 25), in lesion count reduction (MD -3, 95% CI -
5.18 to -0.82; P = 0.007) and physicians’ assessments of marked improvement or complete remission 
(RR 1.18, 95% CI 1.03 to 1.36; P = 0.02; NNTB = 9, 95% CI 5 to 50). There was no difference in number 
of patients (299 in total) experiencing an adverse event (RR 1.19, 95% CI 0.74 to 1.92). Certainty of 
evidence was moderate for these outcomes. There was high certainty evidence of no difference in 
improvement of erythema or telangiectasia. 
Remaining systemic treatments 
Results on other systemic treatments are discussed in Supplementary file 1. 
Treatment for phyma  
Surgical therapies including ablative laser therapies have been used with reportedly good results for 
clinically noninflamed phyma, but no eligible RCTs were identified. For clinically inflamed phymas 
both doxycycline and isotretinoin are recommended, but no supporting evidence based on RCTs is 
available.8 
Treatment for ocular features 
One study with 37 patients (unclear risk of bias) showed that ciclosporin ophthalmic emulsion 0.05% 
twice daily improved quality of life compared to artificial tears as assessed with the Ocular Surface 
Index (OSDI) (scale 0 to 100, 100 = worst).119 MD after three months was -8.6 (95% CI -15.42 to -1.78; 
P = 0.01). The physicians used the Schirmer’s test which demonstrated a MD of 4.1 mm (95% CI 1.66 
to 6.54; P = 0.001), confirming improved tear production, and increased tear break-up time (TBUT) 
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(MD 3.6 seconds, 95% CI 2.59 to 4.61; P < 0.001). There was no difference in number of participants 
with an adverse event. Low certainty evidence for all outcomes. 
Ciclosporin ophthalmic emulsion twice daily was compared with doxycycline 100 mg twice daily for 
the first month followed by two months once daily in a study at high risk of bias (38 participants).14 
Quality of life assessed with the OSDI was MD -8.81, 95% CI -14.32 to -3.32; P = 0.002) favouring 
ciclosporin ophthalmic emulsion. This was confirmed by patients’ assessments based on a symptom 
score (0 to 9, higher = worse) with a MD of -1.85 (95% CI -2.60 to -1.10; P < 0.001). The Schirmer’s 
test (MD 2.11 mm, 95% CI 0.82 to 3.40; P = 0.001), TBUT (MD 2.32, 95% CI 0.81 to 3.83; P = 0.003), 
the eyelid score and the cornea/conjunctival sign score all favoured ciclosporin ophthalmic 
emulsion. Low certainty evidence for all outcomes. 
One study at unclear risk of bias (130 participants) evaluated omega 3 fatty acids (180 mg 
eicosapentaenoic acid and 120 mg docosahexaenoic acid) one capsule twice daily versus placebo 
twice daily for dry eyes in rosacea.16 Moderate certainty evidence for all outcomes. Participants used 
the Dry Eye questionnaire and Scoring System (DESS) to evaluate this outcome (0–6 mild, 6.1–12 
moderate, 12.1–18 severely symptomatic dry eye). The mean change from baseline was -5.30 (SD 
1.52) in the 65 participants treated with omega 3 fatty acids compared with -0.20 (SD 1.59) in the 65 
participants treated with placebo (MD -5.10, 95% CI -5.63 to -4.57; P < 0.001). MD of the Schirmer’s 
test (MD 1.70 mm, 95% CI 0.62 to 2.78; P = 0.002), TBUT (MD 3.30 seconds, 95% CI 2.86 to 3.74; P < 
0.001) and Meibom gland score (lower score is better)(MD -1.28, 95% CI -1.53 to -1.03; P < 0.001) all 
favoured omega 3 fatty acids. 
Combination of treatments 
One study (unclear risk of bias) with 190 patients examined the combination of brimonidine 0.33% 
gel in the morning with ivermectin 1% cream in the evening (to address both persistent erythema 
and papules/pustules) versus vehicles.42 According to participants’ assessments (good or 
excellent)(RR 1.42, 95% CI 1.12 to 1.80; P = 0.004; NNTB = 4, 95% CI 3 to 13) and the physician's 
global assessment (clear or almost clear)(RR 1.66, 95% CI 1.18 to 2.35; P = 0.004; NNTB = 4, 95% CI 2 
to 13), combined treatment was effective in treating both features, with reported reductions of 
erythema (RR 1.84,1.38 to 2.46; P < 0.0001; NNTB = 3, 95% CI 2 to 5) and papules/pustules. The 
percentage reduction from baseline was 78.3% for the active treatment group versus 65.5% for the 
vehicles group. 
One study assessed at unclear risk of bias in 72 participants that examined combining doxycycline 40 
mg with topical metronidazole versus metronidazole alone was not specifically designed to treat 
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more than one feature (focussing on papules/pustules rather than on erythema).98 The results of this 
study indicated that combining treatments had a beneficial effect on more than one feature.  
Maintenance treatments 
Three RCTs addressed the effectiveness of combined maintenance treatments following disease 
control. Topical metronidazole 0.75%, ivermectin 1% and azelaic acid 15% gel seemed effective and 
safe for maintenance therapy.41,91 
DISCUSSION 
This updated review including 152 studies focuses on studies and comparisons that were likely to 
provide evidence-based and reliable treatment options, within a phenotype approach. 
For transient reduction of persistent erythema, there is high certainty evidence to support the 
efficacy and safety of brimonidine gel and moderate certainty evidence for oxymetazoline cream 
over 12 hours after application. Both topical treatments probably result in little to no difference in 
number of participants experiencing an adverse event when compared with vehicle (moderate 
certainty evidence). 
 
For persistent erythema and telangiectasia, there was low to moderate certainty evidence of the 
efficacy of (long) pulsed dye laser, Nd:YAG laser and intense pulsed light therapy. 
For papules/pustules of rosacea, there is high certainty evidence that topical azelaic acid and topical 
ivermectin reduce lesion counts, and moderate certainty evidence for topical metronidazole and 
topical minocycline. It still needs to be established whether topical azelaic acid is more effective than 
topical metronidazole, but topical ivermectin appeared slightly more effective than topical 
metronidazole (moderate certainty evidence). 
As for systemic treatments of papules/pustules, there is low certainty evidence that tetracycline is 
effective and moderate certainty evidence for doxycycline (40 mg). There is low certainty evidence 
that 40 mg doxycycline is at least as effective as 100 mg, with fewer adverse events with 40 mg. The 
evidence for the efficacy and safety of low dose minocycline 45 mg is of low certainty and of very 
low certainty for azithromycin. There is probably little to no difference between minocycline 100 mg 
and doxycycline 40 mg (moderate certainty evidence). Serious adverse events have been reported in 
rare cases with minocycline like autoimmune hepatitis, lupus erythematosus and hyperpigmentation 
of the skin and tissues.4 Low dose isotretinoin 0.25 mg/kg results in far more participants with 
minimum 90% lesion count reduction when compared with placebo (high certainty evidence). 
Isotretinoin is known to be teratogenic and should therefore not be prescribed to pregnant women 
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or women that are trying to become pregnant.4 Compared to doxycycline (100 mg tapered to 50 mg 
after two weeks), low dose isotretinoin 0.3 mg/kg probably results in a small effect, but that 
difference in reducing lesion counts may not be important. Both oral isotretinoin and oral 
doxycycline showed important reductions in lesion counts (moderate certainty evidence). 
For most treatments, or combinations thereof, there is no clear evidence favouring any with regard 
to higher remission rates or fewer adverse events. However, more participants experienced an 
adverse event with topical azelaic acid, topical minocycline and oral isotretinoin, when compared 
with vehicle or placebo. 
No studies could be included that addressed treatment of phymatous rosacea. 
For ocular rosacea, ciclosporin 0.05% ophthalmic emulsion was shown to be more beneficial than 
artificial tears (low certainty evidence). Ciclosporin 0.05% was also more effective than doxycycline 
200 mg for the first month and 100 mg for the following two months for all the addressed outcomes 
(low certainty evidence). Omega 3 fatty acids improved symptoms of dry eyes and improved tear 
gland function (moderate certainty evidence). 
Combination of treatments 
One study demonstrated that combination of brimonidine gel in the morning and ivermectin cream 
in the evening was effective in treating both erythema and papules/pustules compared with 
vehicles.42 
Maintenance treatments 
Topical metronidazole 0.75%, ivermectin 1% and azelaic acid 15% gel seem effective and safe as a 
maintenance treatment regarding papules/pustules. Other maintenance treatments for rosacea 
have not been addressed in RCTs. 
Agreements and disagreements with other studies or reviews 
Since the last update of this review in 2015,161 a number of other reviews or guidelines have been 
published.162-166 The Canadian Clinical Practice guidelines for rosacea, published in 2016, used the 
2015 version of this review as a source of clinical evidence and basis for making recommendations 
using the GRADE approach.162 
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 A Swiss S1 guideline for the treatment of rosacea has been published in which assessments of 
evidence (A-E) were used, and 13 national experts on rosacea reached consensus on 
recommendations.163 They concluded that there was level A evidence (no major design flaws and at 
least one double-blind RCT) for pimecrolimus, topic retinoids, topical permethrin, topical benzoyl 
peroxide/clindamycin, topical erythromycin and topical dapsone, oral zinc sulphate and oral 
ampicillin, on which we clearly disagree. There were no details on inclusion criteria for studies, 
neither basis of appraisal of quality nor judgements on the risk of bias. No patients or patient 
advocacy groups were included and the guideline appeared solely reliant on the contribution of 
expert panels. In contrast, and in terms of recognising the significant impact of this condition on 
patients, we have tried to ensure that we received timely, patient-relevant input at all stages of 
conducting and reporting this review and have included two patients as co-authors. Furthermore, 
we applied the widely adopted GRADE approach to rate the certainty of evidence for our predefined 
outcomes of the most clinically relevant comparisons. 
The global ROSacea COnsensus panel (ROSCO), an international panel of dermatologists and 
ophthalmologists developed recommendations for diagnosis, classification and treating rosacea, on 
a phenotype rather than subtype approach.6,8 The classification recommendations from that 
consensus were adopted in this update. 
Three reviews on topical ivermectin in rosacea have been published.164-166 One was a narrative 
review describing the pharmacological properties of ivermectin and available data on efficacy and 
tolerability.164 Another was a systematic review with clinical guideline recommendations in which 
the Jadad score (randomisation, double blinding and dropouts) was used to assess risk of bias but 
not a key criterion (concealment of treatment allocation).165  Nevertheless, their conclusions are in 
concordance with those in this review. As head-to-head studies comparing various topical 
treatments are generally lacking, a network meta-analysis comparing the efficacy, safety and 
tolerability of topical ivermectin with other currently available topical agents has been conducted.166 
This study "expanded and built upon" earlier versions of our review161,167 and was conducted and 
reported robustly. The authors concluded that topical ivermectin appeared to be more effective 
than other topical treatment options for papules/pustules of rosacea, with similar safety and 
tolerability. 
Limitations of our review were that the lack of response from investigators regarding missing trial 
details largely resulted in less favourable risk of bias assessments (unclear as opposed to low risk). 
Unfortunately, our outcomes time until improvement and duration of remission were not or 
minimally addressed in the studies. The lack of standardised and validated scales was challenging for 
pooling data. Scales should be developed with greater focus on specific features rather than 
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conflation of multiple features into a single scale as previously done with the subtype approach. This 
focus will provide greater clarity on the effect of interventions on distinct rosacea features. As an 
example, this would avoid the current conundrum of extracting the effect on persistent erythema 
versus perilesional erythema of inflammatory lesions in studies on "papulopustular rosacea". 
In conclusion, we have summarized the data and most pivotal comparisons of RCTs for rosacea in a 
phenotype-led approach providing certainty of evidence for predefined outcomes. Supplementary 
file 1 is the complete and latest updated version of the systematic review “Interventions for 
rosacea”, which includes all 93 comparisons, including 25 Summary of findings tables. This review 
can therefore be the basis for developing or updating evidence-based guidelines and for guidance in 
clinical decision making.  
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Table 1 GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the 
effect  
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely 
to be close to the estimate of the effect, but there is a possibility that it is substantially different  
Low certainty: Our confidence in the effect estimate is limited: The true effect may be 
substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely 
to be substantially different from the estimate of effect  
Footnote: http://gradepro.org  
 
 
